Pharmacogenomic Testing in the Asthma Clinic: Will Inhaled Corticosteroids Lead the Way?

Pharmacogenomics: Human Genome Project Information. U.S. Department of Energy Genome Programs. http://genomics.energy.gov 2011. www.ornl.gov/sci/techresources/Human_Genome/medicine/pharma.shtml. 2012 January 6.

Hudson KL . Genomics, health care, and society. N Engl J Med, 2011; 365:1033–1041.

Kalow W . Pharmacogenomics: historical perspective and current status. Methods Mol Biol, 2005; 311:3–15.

Table of Pharmacogenomic Biomarkers in Drug Labels. Food and Drug Administration. www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. 2012 January 4.

Drazen JM . A step toward personalized asthma treatment. N Engl J Med, 2011; 365:1245–1246.

Altman RB . Pharmacogenomics: “noninferiority” is sufficient for initial implementation. Clin Pharmacol Ther, 2011; 89:348–350.

Paugh SW , Stocco G , McCorkle JR , Diouf B , Crews KR , Evans WE . Cancer pharmacogenomics. Clin Pharmacol Ther, 2011; 90:461–466.

Relling MV , Klein TE . CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther, 2011; 89:464–467.

Mrazek DA , Lerman C . Facilitating clinical implementation of pharmacogenomics. JAMA, 2011; 306:304–305.

Kobilka BK , Dixon RA , Frielle T et al. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA, 1987; 84:46–50.

dbSNP Short Genetic Variations. National Center for Biotechnology Information. www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=154. 2012 January 6.

Lima JJ , Thomason DB , Mohamed MH , Eberle LV , Self TH , Johnson JA . Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther, 1999; 65:519–525.

Martinez FD , Graves PE , Baldini M , Solomon S , Erickson R . Association between genetic polymorphisms of the beta 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest, 1997; 100:3184–3188.

Choudhry S , Ung N , Avila PC et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med, 2005; 171:563–570.

Drysdale CM , McGraw DW , Stack CB et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA, 2000; 97:10483–10488.

Silverman EK , Kwiatkowski DJ , Sylvia JS et al. Family-based association analysis of B2-adrenergic receptor polymorphisms in the Childhood Asthma Management Program. J Allergy Clin Immunol, 2003; 112:870–876.

Hawkins GA , Tantisira K , Meyers DA et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med, 2006; 174:1101–1109.

Taylor DR , Epton MJ , Kennedy MA et al. Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma. Am J Respir Crit Care Med, 2005; 172:700–703.

Hall IP , Blakey JD , Al Balushi KA et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet, 2006; 368:771–779.

Tsai HJ , Shaikh N , Kho JY et al. beta(2)-Adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. Hum Genet, 2006; 119:547–557.

Blake KV , Feng H , Tantisira KG , Weiss ST , Lima JJ . Bronchodilator response and beta2-adrenergic (ADRB2) haplotype tagging single nucleotide polymorphisms (htSNPs) Am J Respir Crit Care Med, 2008; 177:A568.

Litonjua AA , Tantisira KG , Lasky-Su JA et al. Genome-wide association analysis of bronchodilator response in asthma. Am J Respir Crit Care Med, 2008; 177:A776.

Israel E , Drazen JM , Liggett SB et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med, 2000; 162:75–80.

Israel E , Chinchilli VM , Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet, 2004; 364:1505–1512.

Hancox RJ , Sears MR , Taylor DR . Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J, 1998; 11:589–593.

Taylor DR , Drazen JM , Herbison GP , Yandava CN , Hancox RJ , Town GI . Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax, 2000; 55:762–767.

Wechsler ME , Lehman E , Lazarus SC et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med, 2006; 173:519–526.

Lee DK , Currie GP , Hall IP , Lima JJ , Lipworth BJ . The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol, 2004; 57:68–75.

Bleecker ER , Yancey SW , Baitinger LA et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol, 2006; 118:809–816.

Bleecker ER , Postma DS , Lawrance RM , Meyers DA , Ambrose HJ , Goldman M . Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet, 2007; 370:2118–2125.

Bleecker ER , Lawrance R , Ambrose H , Goldman M . Beta2-adrenergic receptor Gly16Arg variation: effect on response to budesonide/formoterol (BUD/FM) or budesonide (BUD; post-formoterol) in children and adolescents with asthma. Am J Respir Crit Care Med, 2008; 177:A776.

Bleecker ER , Lawrance RM , Ambrose HJ , Goldman M . Beta2-adrenergic receptor gene polymorphisms: is Arg/Arg genotype associated with serious adverse events during treatment with budesonide and formoterol in one pressurized metered-dose inhaler (BUD/FM pMDI) within racial groups? Am J Respir Crit Care Med, 2008; 177:A775.

Anderson W , Bacanu SA , Bleecker ER et al. A prospective haplotype analysis of beta2-adrenergic receptor polymorphisms and clinical response to salmeterol and salmeterol/fluticasone propionate. Am J Respir Crit Care Med, 2008; 177:A775.

Wechsler ME , Kunselman SJ , Chinchilli VM et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet, 2009; 374:1754–1764.

Tantisira KG , Lasky-Su J , Harada M et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med, 2011; 365:1173–1183.

Malmstrom K , Rodriguez-Gomez G , Guerra J et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group [see comments] Ann Intern Med, 1999; 130:487–495.

Szefler SJ , Phillips BR , Martinez FD et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol, 2005; 115:233–242.

Drazen JM , Silverman EK , Lee TH . Heterogeneity of therapeutic responses in asthma. Br Med Bull, 2000; 56:1054–1070.

Wu AC , Tantisira K , Li L , Schuemann B , Weiss S . Repeatability of response to asthma medications. J Allergy Clin Immunol, 2009; 123:385–390.

Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med, 2000; 343:1054–1063.

Tantisira KG , Lake S , Silverman ES et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet, 2004; 13:1353–1359.

Szczepankiewicz A , Breborowicz A , Sobkowiak P , Popiel A . No association of glucocorticoid receptor polymorphisms with asthma and response to glucocorticoids. Adv Med Sci, 2008; 53:245–250.

Dijkstra A , Koppelman GH , Vonk JM , Bruinenberg M , Schouten JP , Postma DS . Pharmacogenomics and outcome of asthma: no clinical application for long-term steroid effects by CRHR1 polymorphisms. J Allergy Clin Immunol, 2008; 121:1510–1513.

Mougey EB CC , Tantisira K , Blake KV , Peters SP , Wise RA , Weiss ST , Lima JJ . Response to fluticasone and montelukast therapies are inversely associated with a common variant of the corticotropin releasing hormone receptor 1 (CRHR1) gene. Am J Respir Crit Care Med, 2011; 183:A4080.

McGeachie M , Wu AC , Lima JJ , Peters SP , Irvin CG , Weiss ST , Tantisira K . Multitrial, multigenic predictive modeling of steroid treatment response in asthmatic adults. Am J Respir Crit Care Med, 2011; 183:A6183.

Little J , Higgins JP , Ioannidis JP et al. STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med, 2009; 6:e22.

Kitch BT , Paltiel AD , Kuntz KM et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest, 2004; 126:1875–1882.

Rogers AJ , Tantisira KG , Fuhlbrigge AL et al. Predictors of poor response during asthma therapy differ with definition of outcome. Pharmacogenomics, 2009; 10:1231–1242.

National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institutepublication no. 08-40512007.

Simundic AM . Methodological issues of genetic association studies. Clin Chem Lab Med, 2010; 48:S115–S118.

Li M , Li C , Guan W . Evaluation of coverage variation of SNP chips for genome-wide association studies. Eur J Hum Genet, 2008; 16:635–643.

HumanOmni5-Quad BeadChip Kit. www.illumina.com/products/humanomni5-quad_beadchip_kit.ilmn?sciid=2011101IBN3&utm_campaign=omni5_gwas_banner_large_internal&utm_medium=banner&utm_source=illumina.com/applications/gwas.ilmn. 2012 January 10.

Handbook: help me understand genetics: genomics research. Services DoHH. Genetics Home Reference: Your Guide to Understanding Genetic Conditions. Bethesda: U.S. National Library of Medicine, 2012.

2011 Clinical Trial Costs Are Rising Rapidly. 2011. www.pharmalot.com/2011/07/clinical-trial-costs-for-each-patient-rose-rapidly/. 2011 September 30.

Phase 3 Clinical Trial Costs Exceed $26,000 per Patient. PR Newswire, 2006. www.lifesciencesworld.com/news/view/11080. 2011 September 30.

Phillips KA , Veenstra DL , Oren E , Lee JK , Sadee W . Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA, 2001; 286:2270–2279.

Wang L . Pharmacogenomics: a systems approach. Wiley Interdiscip Rev Syst Biol Med, 2010; 2:3–22.

Meyers DA . Genetics of asthma and allergy: what have we learned? J Allergy Clin Immunol, 2010; 126:439–446quiz 47–48.